Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in pulmonary hypertension associated with left ventricular systolic dysfunction
NL-OMON36280Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of riociguat in pulmonary hypertension due to left heart disease (PH-LHD) and heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Bayer. Primary endpoint: Change from baseline in mean pulmonary artery pressure at rest. Started Sep 2010; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON36280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36280.